极低密度脂蛋白
载脂蛋白B
内分泌学
甘油三酯
内科学
分泌物
脂蛋白
脂解
脂肪肝
脂肪生成
化学
生物
内生
载脂蛋白E
肝细胞
多不饱和脂肪酸
脂肪性肝炎
生物化学
PCSK9
载脂蛋白C2
过氧化物酶体
微粒体甘油三酯转移蛋白
乳糜微粒
高密度脂蛋白
作者
David J. Sherman,Lei Liu,Edward L. LaGory,Preston Fordstrom,Danielle Pruitt,Jose Barreda,Joy G. Cagmat,Jiansong Xie,John Ferbas,Ingrid C. Rulifson,Raymond J. Deshaies
出处
期刊:Cell Reports
[Cell Press]
日期:2025-10-01
卷期号:44 (10): 116371-116371
被引量:10
标识
DOI:10.1016/j.celrep.2025.116371
摘要
The common variant PNPLA3-I148M, globally, is the most significant genetic risk factor for fatty liver disease. However, it is unclear precisely how I148M drives disease risk. Using human hepatoma cells expressing endogenous I148M, we find that the variant impairs cellular secretion of apolipoprotein B (ApoB), the scaffolding protein of very-low-density lipoprotein (VLDL). This is not due to loss-of-function of wild-type PNPLA3. Expression of human I148M in primary hepatocytes and mice also hinders VLDL secretion. Lipidomic profiling reveals a shift from polyunsaturated phosphatidylcholine to polyunsaturated triglycerides in I148M cells, reducing membrane fluidity and, concomitantly, VLDL biogenesis. ApoB secretion is substantially rescued in I148M cells overexpressing ABHD5/CGI-58, an I148M-binding partner that normally activates ATGL/PNPLA2-mediated triglyceride lipolysis. Conversely, knocking down CGI-58 or PNPLA2 mimics I148M. We propose that I148M is a neomorph that exacerbates fatty liver risk by simultaneously impeding two major CGI-58-dependent pathways for liver triglyceride clearance: lipolysis and secretion.
科研通智能强力驱动
Strongly Powered by AbleSci AI